Etomidate Mechanism of Action
Etomidate produces general anesthesia by acting as a positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of the neurotransmitter γ-aminobutyric acid (GABA) in the central nervous system. 1, 2
Primary Mechanism
Etomidate potentiates GABA-A receptor activity by binding to specific transmembrane allosteric sites, particularly near β2M286 residues in the M3 domains of the receptor. 3, 4
The drug demonstrates state-dependent binding, with significantly higher affinity for activated receptors (1.1-2.2 μM) compared to inactive receptors (14 μM), which is a fundamental characteristic of allosteric agonists. 4
Etomidate can both directly activate GABA-A receptors and modulate GABA-activated currents, functioning through Monod-Wyman-Changeux allosteric co-agonism mechanisms. 3
Receptor-Specific Effects
The drug modulates multiple modes of GABA-A receptor-mediated inhibition, including:
- Phasic inhibition (synaptic α1β2γ2 receptors)
- Tonic inhibition (extrasynaptic α4β2δ receptors)
- Spillover inhibition (dynamic recruitment of extrasynaptic receptors) 5
In thalamocortical relay neurons, etomidate significantly inhibits action-potential discharge through facilitation of both synaptic and extrasynaptic GABA-A receptors, with enhanced tonic inhibition being the dominant mechanism. 5
Clinical Pharmacology Implications
The GABA-A receptor potentiation results in rapid onset of anesthesia within one minute with duration of 3-5 minutes at standard 0.3 mg/kg dosing. 1
Etomidate produces 20-30% reduction in cerebral blood flow and moderate lowering of intracranial pressure, with cerebral oxygen utilization decreasing proportionally to blood flow reduction. 1
The mechanism involves no histamine release and produces minimal cardiovascular depression, distinguishing it from other anesthetic agents. 1